Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Our bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, we have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Our vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine.
With our mission to improve health and well-being of people around the world, we have gone down a path that nobody wishes to explore. Our extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate our ongoing commitment to all people who rely on our products.